• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

by MM360 Staff | Nov 2, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

by MM360 Staff | Nov 2, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

by MM360 Staff | Nov 1, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement

by MM360 Staff | Oct 31, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression

by MM360 Staff | Oct 31, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes

by MM360 Staff | Oct 28, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • FDA approves ziftomenib to treat some relapsed leukemia patients
  • (no title)
  • The challenge of non-transplant eligible, newly diagnosed multiple myeloma
  • Camera pill to find pancreatic cancer seeks breakthrough status
  • Camera pill to find pancreatic cancer seeks breakthrough status
  • Tinostamustine named orphan drug for treating malignant gliomas
  • New combination therapy approach may improve ovarian cancer care
  • FDA approves 1st treatment for high-risk smoldering myeloma
  • CAR T-cell therapy candidate yields lasting response in tough lymphoma
  • Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT